Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492636 | 0.93 | LTB4R (0.41) | ADORA3LTB4RSMN1; SMN2MAPTHTT | |
| SCHEMBL24329824 | 0.93 | ADORA3 (0.39) | ADORA3SMN1; SMN2MAPTTP53ALDH1A1 | |
| SCHEMBL13401854 | 0.93 | ABCB1 (0.39) | ADORA3LTB4RSMN1; SMN2TP53HTT | |
| SCHEMBL19206667 | 0.92 | LTB4R (0.39) | ADORA3LTB4RMAPTHTTALDH1A1 | |
| SCHEMBL17696299 | 0.91 | ADORA3 (0.36) | ADORA3LTB4RSMN1; SMN2MAPTTP53 | |
| SCHEMBL20543595 | 0.90 | PDE3B (0.38) | ADORA3LTB4RSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL20543423 | 0.90 | PDE3B (0.38) | ADORA3LTB4RSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL21751359 | 0.90 | ADORA3 (0.37) | ADORA3HTTALDH1A1CYP3A4CDC7 | |
| SCHEMBL25760289 | 0.90 | KMT2A (0.36) | SMN1; SMN2MAPTTP53ALDH1A1HPGD | |
| SCHEMBL19206655 | 0.89 | SMN1; SMN2 (0.34) | ADORA3LTB4RSMN1; SMN2MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORP (US) | 2025-11-06 | — | — | US | claimed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | claimed |
| EP-3416968-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2018-12-26 | — | — | EP | claimed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | claimed |
| WO-2017142852-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2017-08-24 | — | — | WO | claimed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | claimed |
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391973-B2 | Substituted imidazo[1,2-α]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | disclosed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | disclosed |
| US-20170121755-A1 | COELENTERAZINE ANALOGS | JNC CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-20170121755-A1 | COELENTERAZINE ANALOGS | JNC CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-9567623-B2 | Coelenterazine analogs | JNC CORPORATION (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567623-B2 | Coelenterazine analogs | JNC CORPORATION (JP) | 2017-02-14 | — | — | US | disclosed |
| US-20140302539-A1 | COELENTERAZINE ANALOGS | JNC CORPORATION (JP) | 2014-10-09 | — | — | US | disclosed |
| US-20140302539-A1 | COELENTERAZINE ANALOGS | JNC CORPORATION (JP) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | ADORA3 4146/4885LTB4R 3523/4885SMN1; SMN2 2626/4885 |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | ADORA3 1167/4885LTB4R 2862/4885SMN1; SMN2 4671/4885 |
| US-20170121755-A1 | COELENTERAZINE ANALOGS | GLB1, CRY1, GTF3C5 | ADORA3 3043/4885LTB4R 2716/4885SMN1; SMN2 4443/4885 |
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | ADORA3 1098/4885LTB4R 3723/4885SMN1; SMN2 4438/4885 |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | GLB1, PGLS, AADAC | ADORA3 1073/4885LTB4R 3358/4885SMN1; SMN2 4257/4885 |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | ADORA3 3089/4885LTB4R 3143/4885SMN1; SMN2 3970/4885 |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | ADORA3 3089/4885LTB4R 3143/4885SMN1; SMN2 3970/4885 |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | ADORA3 1167/4885LTB4R 2862/4885SMN1; SMN2 4671/4885 |
| US-20140302539-A1 | COELENTERAZINE ANALOGS | GLB1, CRY1, GTF3C5 | ADORA3 3043/4885LTB4R 2716/4885SMN1; SMN2 4443/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | ADORA3 1098/4885LTB4R 3723/4885SMN1; SMN2 4438/4885 |
| US-12391973-B2 | Substituted imidazo[1,2-α]pyrazines as luciferase substrates | PGLS, GLB1, AADAC | ADORA3 1361/4885LTB4R 3694/4885SMN1; SMN2 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.